Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Table 2 Antimicrotubule trials: survival outcomes.

Trial	Treatment arms	Overall survival			Progression-free survival or TTP
		N	Median (mo)	Statistical comparison	N	Median (mo)	Statistical comparison
Tannock, 2004 [64]	docetaxel q 3 wks prednisone	335	18.9	HR = 0.76 (95% CI, 0.62–0.94), p = 0.009	NR
	docetaxel q wk prednisone	334	17.4	HR = 0.91 (95% CI, 0.75–1.11) p = 0.36
	Mitoxantrone prednisone	337	16.5	NA
Petrylak, 2004 [63]	Docectaxel EMP	338	17.5	HR = 0.80 (95% CI, 0.67–0.97) p = 0.02	324	6.3	HR = 0.73 (95% CI, 0.63–0.86) p < 0.001 (TPP)
	Mitoxantrone prednisone	336	15.6		324	3.2
Abratt, 2004 [62]	Vinorelbine hydrocortisone ± AGM	206	14.7	p = 0.95	206	3.7	HR = 0.71 p = 0.055 (unadjusted) p = 0.005 (adjusted)*
	hydrocortisone ± AGM	208	15.2		208	2.8
Berry, 2001 [84]	paclitaxel EMP	166	15.1	p = 0.11	166	NR	p = 0.08
	Paclitaxel		12.9
Hudes, 1999 [61]	vinblastine EMP	95	11.9	p = 0.08	98	3.7	p < 0.0004† (TTP)
	Vinblastine	98	9.2		95	2.2
Iversen, 1997 [65]	EMP	61	9.4	p = 0.09	60	2.2
	Placebo	68	6.1		67	5.0
Johansson, 1991 [66]	EMP	51	NR	p = 0.23	51	NR	p = 0.28
	MPA	51			51
De Kernion, 1988 [67]	EMP	102	NR	p = NS	102	NR	p = NS
	Flutamide	101			101
Murphy, 1979 [68]	EMP prednimustine	54	9.3	p = NS	NR
	prednimustine	62	9.0

*Adjusted for age, baseline hemoglobin, performance status, and alkaline phosphatase, and number of prior hormonal manipulations; †based on one-sided significance testing.
Abbreviations: AGM – aminoglutethimide; CI – confidence interval; EMP – estramustine phosphate; HR – hazard ratio; mo – months; MPA – medroxyprogesterone acetate; N – number; NA – not applicable; NR – not reported; NS – non-significant; q – every; TTP – time-to-progression; wk(s) – week(s).

ISSN: 1471-2407